Trials / Conditions / HER2 Gene Mutation

HER2 Gene Mutation

19 registered clinical trials studyying HER2 Gene Mutation — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutat NCT07436858	The Netherlands Cancer Institute	Phase 1
Active Not Recruiting	Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617	SystImmune Inc.	Phase 1
Recruiting	HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155	Radiopharm Theranostics, Ltd	EARLY_Phase 1
Active Not Recruiting	Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliar NCT06178445	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Recruiting	Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer NCT06449989	Blokhin's Russian Cancer Research Center	—
Recruiting	A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer NCT06123338	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer NCT05673512	SUNHO（China）BioPharmaceutical CO., Ltd.	Phase 2 / Phase 3
Recruiting	Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinom NCT06383533	Zhejiang Cancer Hospital	Phase 2
Unknown	IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant T NCT05991518	SUNHO（China）BioPharmaceutical CO., Ltd.	Phase 1 / Phase 2
Active Not Recruiting	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer NCT05650879	Enliven Therapeutics	Phase 1
Terminated	Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors NCT05511844	Orum Therapeutics USA, Inc.	Phase 1
Recruiting	Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients NCT05274048	Fox Chase Cancer Center	Phase 1
Completed	Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers NCT06083662	Korea University Guro Hospital	Phase 2
Recruiting	Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187	Dana-Farber Cancer Institute	Phase 2
Unknown	The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor NCT04179656	Tianjin Medical University Second Hospital	Phase 2
Completed	Her2-positive Lung Cancer Treated With Dedicated Drug NCT03845270	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
Completed	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079	Klus Pharma Inc.	Phase 1 / Phase 2
Unknown	Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer NCT03412383	Peking Union Medical College	Phase 2
Completed	Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) NCT02979821	Korean Association for the Study of Targeted Therapy	Phase 2